Novavax COVID-19 Vaccine Enters 5th Phase 3 Trial in the US

Our Government Also Considering Introduction
US and UK Already Have Supply Contracts

[Image source=Reuters Yonhap News]

[Asia Economy New York=Correspondent Baek Jong-min] The COVID-19 vaccine developed by the American pharmaceutical company Novavax, which South Korea is also planning to introduce, has become the fifth vaccine in the United States to begin Phase 3 clinical trials.

According to CNN, Novavax announced on the 28th (local time) that it will start Phase 3 clinical trials of its COVID-19 vaccine in the United States and Mexico. This is the fifth vaccine following Pfizer and Moderna, which are already being administered, and AstraZeneca and Johnson & Johnson, which are currently in Phase 3 trials.

This Phase 3 trial will be conducted on 30,000 participants aged 18 and older. Novavax plans to conduct the trial in regions with high COVID-19 infection rates to better observe the vaccine's efficacy.

Novavax originally planned to start Phase 3 trials in the United States in mid-October but postponed twice due to issues expanding the vaccine manufacturing process.

Novavax has contracts to supply 100 million doses to the United States and 60 million doses to the United Kingdom. The South Korean government is also negotiating with Novavax regarding vaccine purchases.

This content was produced with the assistance of AI translation services.